Cargando…
Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization
Sphingosine‐1‐phosphate (S1P), the circulating HDL‐bound lipid mediator that acts via S1P receptors (S1PR), is required for normal vascular development. The role of this signaling axis in vascular retinopathies is unclear. Here, we show in a mouse model of oxygen‐induced retinopathy (OIR) that endot...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165359/ https://www.ncbi.nlm.nih.gov/pubmed/36912000 http://dx.doi.org/10.15252/emmm.202216645 |
_version_ | 1785038252840845312 |
---|---|
author | Niaudet, Colin Jung, Bongnam Kuo, Andrew Swendeman, Steven Bull, Edward Seno, Takahiro Crocker, Reed Fu, Zhongjie Smith, Lois E H Hla, Timothy |
author_facet | Niaudet, Colin Jung, Bongnam Kuo, Andrew Swendeman, Steven Bull, Edward Seno, Takahiro Crocker, Reed Fu, Zhongjie Smith, Lois E H Hla, Timothy |
author_sort | Niaudet, Colin |
collection | PubMed |
description | Sphingosine‐1‐phosphate (S1P), the circulating HDL‐bound lipid mediator that acts via S1P receptors (S1PR), is required for normal vascular development. The role of this signaling axis in vascular retinopathies is unclear. Here, we show in a mouse model of oxygen‐induced retinopathy (OIR) that endothelial overexpression of S1pr1 suppresses while endothelial knockout of S1pr1 worsens neovascular tuft formation. Furthermore, neovascular tufts are increased in Apom (−/−) mice which lack HDL‐bound S1P while they are suppressed in Apom ( TG ) mice which have more circulating HDL‐S1P. These results suggest that circulating HDL‐S1P activation of endothelial S1PR1 suppresses neovascular pathology in OIR. Additionally, systemic administration of ApoM‐Fc‐bound S1P or a small‐molecule Gi‐biased S1PR1 agonist suppressed neovascular tuft formation. Circulating HDL‐S1P activation of endothelial S1PR1 may be a key protective mechanism to guard against neovascular retinopathies that occur not only in premature infants but also in diabetic patients and aging people. |
format | Online Article Text |
id | pubmed-10165359 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101653592023-05-09 Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization Niaudet, Colin Jung, Bongnam Kuo, Andrew Swendeman, Steven Bull, Edward Seno, Takahiro Crocker, Reed Fu, Zhongjie Smith, Lois E H Hla, Timothy EMBO Mol Med Reports Sphingosine‐1‐phosphate (S1P), the circulating HDL‐bound lipid mediator that acts via S1P receptors (S1PR), is required for normal vascular development. The role of this signaling axis in vascular retinopathies is unclear. Here, we show in a mouse model of oxygen‐induced retinopathy (OIR) that endothelial overexpression of S1pr1 suppresses while endothelial knockout of S1pr1 worsens neovascular tuft formation. Furthermore, neovascular tufts are increased in Apom (−/−) mice which lack HDL‐bound S1P while they are suppressed in Apom ( TG ) mice which have more circulating HDL‐S1P. These results suggest that circulating HDL‐S1P activation of endothelial S1PR1 suppresses neovascular pathology in OIR. Additionally, systemic administration of ApoM‐Fc‐bound S1P or a small‐molecule Gi‐biased S1PR1 agonist suppressed neovascular tuft formation. Circulating HDL‐S1P activation of endothelial S1PR1 may be a key protective mechanism to guard against neovascular retinopathies that occur not only in premature infants but also in diabetic patients and aging people. John Wiley and Sons Inc. 2023-03-13 /pmc/articles/PMC10165359/ /pubmed/36912000 http://dx.doi.org/10.15252/emmm.202216645 Text en © 2023 The Authors. Published under the terms of the CC BY 4.0 license. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reports Niaudet, Colin Jung, Bongnam Kuo, Andrew Swendeman, Steven Bull, Edward Seno, Takahiro Crocker, Reed Fu, Zhongjie Smith, Lois E H Hla, Timothy Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization |
title | Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization |
title_full | Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization |
title_fullStr | Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization |
title_full_unstemmed | Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization |
title_short | Therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound S1P suppresses proliferative retinal neovascularization |
title_sort | therapeutic activation of endothelial sphingosine‐1‐phosphate receptor 1 by chaperone‐bound s1p suppresses proliferative retinal neovascularization |
topic | Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165359/ https://www.ncbi.nlm.nih.gov/pubmed/36912000 http://dx.doi.org/10.15252/emmm.202216645 |
work_keys_str_mv | AT niaudetcolin therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization AT jungbongnam therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization AT kuoandrew therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization AT swendemansteven therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization AT bulledward therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization AT senotakahiro therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization AT crockerreed therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization AT fuzhongjie therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization AT smithloiseh therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization AT hlatimothy therapeuticactivationofendothelialsphingosine1phosphatereceptor1bychaperonebounds1psuppressesproliferativeretinalneovascularization |